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Sary We examined the integrin expression in 19 human lung cancer cell lines with monoclonal
antibodies to the integrin subunits a,, a2, a2, a, as, %, A, P2, and P4. We measured their ability to adhere to the
extracellular matrix (ECM) and human umbilical vein endothelial cells (HUVECs). Almost all lies cxpressed
the Pi subunit and approxmately half of the lines expr the P0 subunit; by contrast, non ex d t P2
subunit. Subunits a2, 3as and aiG we frquently expresse whereas very few hnes expressed ml and 4. Most
adhered strongly to ECM (type I colage laminin and fibronectin) in correspondence to their expression
of integrins. Binding by most ines to fibronetin was compleiy inhibited by arginine-glycine-aspartic acid
(RGD) pept. Tlwhree hnes that expressed few or no integrins had very weak ability to adhere to ECM.
Strong binding to HUVECs was found in most lnes, but the three ines had very little ability to adhere to
HUVECs. Binding to HUVECs was strongly inhibited at 4C, under divalent cation-free conditions and by
antibodies to the subunit. These results sugget that lung cancer cells adhere to ECM and endotheal cels
through integrns, espcially the A1 subfamily.
Metastasis is the major cause of mortality in patients with
malignant tumours. It consists of a series of events, of which
the most important are the detachment of cancer cells, their
migration to and then transportation by the drculation,
adhesion to vascular endothelial cells, migration through the
vascular wall and, finally, proliferation in the parenchyma of
the target organs (Nicolson, 1988). The interaction oftumour
cells with vascular endothelial cells is thought to be one of
the most important steps in haematogenous metastasis
(Albelda & Buck, 1990; Chammas & Brentani, 1991).
A dramatic step forward in the analysis of this interaction
was taken with the identification of integrins, a family of
adhesion molecules. The integrins are transmembrane glyco-
proteins that form heterodimers consisting of non-covalently
associated a- and a-subunits (Hynes, 1987; Hemler, 1990).
The majority of integrins can be grouped into several sub-
families defined by the presence of a common A-subunit.
Many receptors for ECM proteins including the integrin
family have been found on tumours (Ruoslahti & Pier-
schbacher, 1987). In the first step of their interaction with
endothelial cells, melanoma (Martin-Padura et al., 1991) and
fibrosarcoma cells (Kawaguchi et al., 1992) adhere to endo-
thelial cells through VLA-4/VCAM-1 interaction. There have
been several studies on integrin expression of lung cancers
(Damjanovich et al., 1992; Mette et al., 1993; Suzuki et al.,
1993) and the ability of lung cancer cells to adhere to ECM
proteins (Mette et al., 1993). The key molecules by which
lung cancer cells interact with endothelial cells remain un-
clear. We have examined the integrin expression of lung
cancer cells and their ability to adhere to ECM proteins and
endothelial cells using 19 lung cancer cell lines. The presence
of integrins on lung cancer cells seems to be necessary for
lung cancer cells to adhere to endothelial cells or ECM
proteins. We discuss the role of integrins on lung cancer cells
during the process of metastasis.
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Material and inERMo7
Lung cancer cell lines
Nimeteen lung cancer cell lines were used in this study. LC18,
LC27, LC81, LC127, LC133, LC142, LC146, LC148 and
LC155 were established in our laboratory (Inoue et al., 1990;
Shijubo et a., 1991) and A549, EBC-1, LClsq, RERF-LC-
MA, SBC-1, SBC-2, SBC-3, SBC-5, Lu134-A-H and LC65C
(Lieber et el., 1976; Terasaki et al., 1986; Imanisi et al.,
1989; Harada et al., 1990) were supplied by the Japan Cancer
Research Resources Bank. LC18, LC81, LC127, LC133,
LC142, LC146, LC155 and A549 were establshed from lung
adenocarcinoma, EBC-1 and LCI-sq from lung squamous
cell carcinoma, LC148, Lu134-A-H, RERF-LC-MA, SBC-1,
SBC-2, SBC-3 and SBC-5 from small-cell lung carcinoma
and LC27 and LC65C from large cell lung carcinoma. These
cell lines were adherent and maintaind in RPMI-1640
medium suplemented with 2 x 10-3 M L-glutamie, 10%
fetal calf serum (FCS), 100 U ml-' penicilln and 100 agml-'
streptomycin (hereafter referred to as the 'complete
medium'). For binding assays, tumour cells were treated with
PBS, pH 7.4, containing 0.05% trypsin (Sigma, St Louis,
MO, USA) and 0.02% EDTA, collected, washed three times
with PBS and resuspended in complete medium. The viability
of tumour cells was more than 95% as judged from the
ability to exclude trypan blue.
Reagents
Human fibronection, laminin and collagen type I were pur-
chased from Chemicon (Temecula, CA, USA). The ECM
proteins were dissolved in Ca2+, Mg2+-free PBS. RGD-
containing peptide (GRGDSP) and III CS CS-1 peptide
(CDELPQLVTLPNLHGPEILDVPST) were purchased from
Iwakiglass Institute, (Tokyo, Japan). RGD peptide is the
recognition site of VLA-3 and VLA-5, and Ill CS CS-1
peptide is the recognition site of VLA-4 (Hynes, 1992).
Detection ofintegrin expression on lung cancer cells oflines
Phenotyping of lung cancer cell lines was performed by
indirect immunofluorescen using saturating amounts of
MAbs to integrin subunits. These are listed in Table I.
Normal mouse or rat IgG was used as a negative control.
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Flow cytometric analysis was carried out using a FACScan
(Becton Dickinson, San Jose, CA, USA). The fraction of
positive cells after background subtraction was recorded for
each sample study.
Binding assays to ECMproteins
Each well of a 48-well culture plate (Costar, Cambridge, MA,
USA) was pretreated with 3001 l of ECM protein solution
(collagen type I, l00OiLgml-'; laminin, lOILgml-'; and
fibronection, 10 tLg ml-') at 4°C overnight. After washing
three times with PBS containing 5 mgml-' bovine serum
albumin (BSA), the remaining uncoated sites were blocked
by incubation with RPMI-1640 containing 5 mg ml-1 BSA at
4°C for 4 h. Twelve thousand tumour cells of each line in
300;Ll of RPMI-1640 containing 1% BSA were added to
each well and then incubated at 37C in 5% carbon dioxide
for 2 h. After incubation, culture supernatant with unbound
cells was removed by gentle aspiration and then washed three
times with RPMI-1640 containing 1% BSA prewarmed to
37C. Interactions between tumour cells and ECM proteins
were examined under phase-contrast microscopy in six ran-
Table I Anti-integrin MAb used
Subunit MAb name Source Reference
a, TS2 7 Dr Martin E. Hemier Hemler et al. (1984)
a. 12F1 Dr Virgil Wood Piscbel et al. (1987)
a3 J134 Dr Tony Albino Fradit et al. (1984)
a4 8F2 Dr Martin Hemler Hemler et al. (1987)
as BIIG2 Dr Caroline Damsky Web et al. (1989)
a6 GoH3 Dr Arnoud Sonnenberg Sonnenberg et al. (1986)
pi AJ2 Dr Tony Albino Careross et al. (1982)
4B4 Coulter Davis et al. (1990)
SG 19 Seikagaku Corp. Miyake et al. (1992)
P-1 L130 Becton Dickinson Springer et al. (1987)
P-1 439-9B Dr Stephen J. Kennel Kennel et al. (1986)
dom fields at a magnification of x 40. Data represent the
number of tumour cells binding to each ECM protein per
mm2 + s.e.m.
Inhibition assays were performed to assess the effect of the
synthetic fragments of fibronectin. Tumour cells pretreated
with l00;gml-' RGD or l00figml- CS-I peptide for 1 h
were added directly to the wells. The binding assays were
carried out as described above.
Binding assays to endothelial cells
HUVECs were purchased from Kurabo (Osaka. Japan).
HUVECs were cultured in eight-well Lab-Tek chambers
(Nunc, Naperville, IL, USA) using a medium of endothelial
cells, E-GM UV (Kurabo), at 37°C in 5% carbon dioxide to
the subconfluent condition and then gently washed three
times with complete medium. Twelve thousand tumour cells
of each lung cancer line in 300gl of complete medium were
placed in the Lab-Tek chambers and incubated at 37°C in
5% carbon dioxide for 12 h. After incubation, chamber
structures of Lab-Tek slides were removed and slide glasses
with silicone gaskets were dipped face down into 50 ml of
washing medium (RPMI-1640 containing 1% FCS) pre-
warmed to 37°C, and washed under gentle agitation for
S min. The chambers were then dried and fixed with
methanol for 3 min. The chambers were stained with Diff-
Quick (Kokusai Reagent, Kobe, Japan), which is a
modification of the Wright and Giemsa staining method. The
degree of binding and infiltration of tumour cells into
HUVECs was evaluated under light microscopic examination
in six random fields at a magnification of x 200. Halo-like
images showing tumour cells infiltrated into HUVECs were
assessed by phase-contrast illumination of the same field.
Data represent means of tumour cell binding and infiltration
per mm2 ± s.e.m.
Assays were performed at 4°C or 37°C for 2 h to investi-
gate the extent to which binding is dependent on energy.
Next, we performed the assays under conditions of 1 mm
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Figure I Integrin expression on lung cancer cell lines. Integrin expression was determined by immunofluorescence using a panel of
monoclonal antibodies against various integrin subunits (Table I). The fraction of positive cells after background subtraction was
recorded for each sample study.
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Figure 2 Integrin expression of lung cancer cells with regard to receptors to ECM proteins [collagen (a) laminin (b) and
fibronectin (c)] and ability of tumour cells to adhere to ECM proteins. Percentages of stained cells are divided into four distinct
levels: -. very low (<5%); 0. low ( ) 5% and <30%); 0. moderate ( > 300%6 and <60%); <. high expression ( ) 60%). Data are
expressed as mean number of tumour cells binding to ECM proteins per mm: + s.e.m.. as described in Materials and methods
section.
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Ca2+, Mg2+ HBSS or Ca2+, Mg2+-free HBSS to investigate
divalent cation dependency of tumour cell binding to
endothelial cells. These media were supplemented with 20%
FCS dialysed three times against PBS for 12 h. The degree of
binding to endothelial cells was evaluated by the same proce-
dure as mentioned above.
Inhibition assays were performed to evaluate the effect of
MAbs to integrin P, subunit on tumour cell binding to
endothelial cells. Five lung cancer cell lines (LC81, LC146,
LC155, A549 and SBC-2) were preincubated with MAbs
[4B4 or SG/19 (40gLg ml-')] to integrin PI subunit or with an
isotype-identical negative control MAb (1C5) to human cer-
vical adenocarcinoma (Koizumi et al., 1988) for 1 h. Follow-
ing preincubation with the MAbs, 12,000 tumour cells were
added directly to the chambers without washing. The binding
assays were carried out as described above. Incubation time
of the assays was I h.
Another senres of inhibition assays was performed to assess
the effect of the synthetic fragments of fibronectin. The
tumour cells were preincubated with 100jg nm1' RGD or
100 ;Lg ml-' CS-l peptide at 3T7C in 5% carbon dioxide for
1 h. Following preincubation with the synthetic fragments,
the tumour cells were added directly to the chambers without
washing. Assays were carried out as described above, except
that the incubation time was 30 min.
Binding inhibition oflung cancer cells tofibronectin using RGD
or CS-I peptide
Binding inhibition assays to fibronectin with RGD or CS-1
peptide were performed using the 17 lung cancer lines that
had adhered strongly to fibronectin (Figure 3). RGD peptide
inhibited the binding of tumour cells to fibronection (Figure
3). RGD peptide inhibited the binding of tumour cells to
fibronectin in nearly all of these lung cancer lines (16/17), but
showed no such action with Lu34-A-H. CS-i1 peptide failed
to block binding of tumour cells to fibronectin in all
examined lines.
Ability oftumour cells to adhere to HUVECs
We examined the ability of lung cancer cells to adhere to and
infiltrate into HUVECs. A typical interaction is shown in
Figure 4. Figure 4a depicts a case of low binding (by SBC-1)
to the HUVECs' surface, and Figure 4b shows strong bind-
ing (by LC27). Figure 4c depicts a halo-like image showing
the tumour cell (LC27) infiltrated into the HUVEC, and
Figure 4d shows simply adhesion of tumour cells (LC155) to
the HUVECs' surface. Data on binding and infiltration by
tumour cells are shown in Figure 5. Tumour cells of most
lung cancer lines showed strong binding to HUVECs and
frequently infiltrated into them. The three lines LC18, SBC-1
and Lul34-A-H had very weak binding to HUVECs and
seldom infiltration.
Results
Expression ofintegrins in lung cancer lines
We examined integrin expression on tumour cells of 19 lung
cancer cell lines using MAbs (Figure 1). Integrin expression
on tumour cells of lung cancer lines is quite heterogeneous.
There was no typical feature of the expression of integrin
subunits on any histological cell types of lung cancer cell
lines. The degree of expression of the a-subunit varied, how-
ever almost all cell lines (17 out of 19) expressed the P,
subunit, and 9 out of 19 lines expressed the P subunit. By
contrast none of them expressed R. The a-subunits most
consistently found on tumour cells of lung cancer lines were
a, (10/19), a3 (14/19), a5 (15/19) and am6 (15/19). A very minor
population of lung cancer lines had a, (1/19) and a4 subunits
(2/19).
Ability oflung cancer cells to adhere to ECMproteins
Since the integrins are known to function as adhesion recep-
tors for ECM proteins, we measured the adhesive properties
of the tumour cells in a cell attachment assay. The expres-
sions of the integrin subunits which function as receptors to
ECM proteins and their properties of adhesion to ECM
proteins are shown in Figure 2. Fourteen of 19 lung cancer
lines had at least one of the integrin subunits that are col-
lagen receptors (VLA-1, VLA-2 and VLA-3) and were able
to adhere to collagen strongly. No VLA-1, VLA-2 or VLA-3
was found in five lines (LC18, LC142, SBC-1, Lu134-A-H
and LC27). LC142 adhered strongly to collagen, but cells of
the remaining four lines failed to adhere to collagen. Seven-
teen of 19 lung cancer lines expressed at least one of the
integrin subunits as laminin receptors (VLA-1, VLA-2, VLA-
3, VLA-6 and a6 p4). Nearly all of the lines (16/17) with
integin laminin receptors were able to adhere strongly to
laminin. SBC-l cells expressed VLA-6, but failed to adhere to
laminin. LC18 expressed only the a 6 subunit but neither the
P nor P4 subunit, and Lu134-A-H expressed none of the
integrin subunits examined in this study. LC18 and Lul34-A-
H failed to adhere to laminin. Sixteen of 19 lung cancer lines
expressed at least one of the integrin subunits that function
as fibronectin receptors (VLA-3, VLA-4 and VLA-5). Lung
cancer cells of these lines adhered strongly to fibronectin.
LC18, SBC-I and LuI34-A-H never expressed VLA-3, VLA-
4 or VLA-5. LC18 and SBC-l failed to adhere to fibronectin,
whereas Lul 34-A-H bound strongly to fibronectin.
Adhesion assays at 4C, andunder divalent cation-free
conditions
Since integrins are known to require energy (Dransfield &
Hogg, 1989) and divalent cations (Statz et al., 1989), we
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and methods section and data are expressed as mean number of
tumour cells binding to fibronectin per mm2 ± s.e.m.
U. I~~~~~~~~~~~~~~~~~~~~470 M. HIRASAWA et at.
a c
t......
*t ..
.!
.:_.
..
P - ...
.h k
d
a_ . _
.#- .-
*-............
*::s.
Fum 4 Representative microphotographs of interactive behaviour between tumour cels and HUVECs. a shows weak (SBC-1)
and b shows strong binding of tumour celk (LC27). c depicts a halo-like ima (arrow) showing the tumour cell (LC27) infiltrated
into the HUVEC and d depicts simple adhesion of tumour cells (LC155). Original magnificaion: a and b, x 235; and c and d
x 470.
performed adhesion assays on HUVECs at 4-C or at 37C
and under conditions with or without divalent cations
(Figure 6). Tumour cell binding to HUVECs was much lower
at 4-C or under divalent cation-free conditions than at 37C
or in the presence of divalent cations.
Inhibition oflhg cancer celladhesion to HUVECs by RGD,
CS& peptide or MAbs to integri PI subwut.
Inhibition assays to HUVECs with the MAbs (4B4 or SG/19)
to the PI subunit were performed (Figure 7). Both MAbs
showed great inhibition of adhesion ranging from 51% to
83% inhibition, in comparison with the binding with an
isotype-matched negative control MAb. Next, assays were
performed using RGD or CS-1 peptide; assays to these failed
to inhibit binding of tumour cells to HUVECs in all
examined ines (data not shown).
Integrins mediate ECM-cell or cell-cell interactions
(Hemker, 1990a). Embryonic development, maintenance of
tissue architecture, inflammatory esponse and wound healing
all involve the intraction of cells with ECM proteins or
neighbouring cells; thus, the integrins play a very important
role in mediatng such events (Hynes, 1987) and the meta-
stasis of malignant tumours (Chammas & Brentani, 1991).
Metastatic subtypes of Lewis lung carcinoma expessed a P4
more frequently than did non-metastatic subtypes (Perrotti et
al., 1990). Rhabdomyosarcoma cells transfected with genes
from VLA-2 became substantially more nmtastatic than the
orginal tumour cells (B.M.C. Chen et al., 1991). Both
antibodis to integrins and synthetc pepides of ECM pro-
teins prevented the formation of the lung nodules in mice
injected with B16 melanoma cells (Humphries et al., 1986).
There is ncreasig evidence that neoplasti transformation is
associated with modification of integrin expression (Dedhar
& Saulnier, 1990). Human lung cancers expressed at least 20
times more £2 subunit RNA mesage than normal adult
human lung tissue (FA. Chen et al., 1991). Modification of
integrin expression may affect the ability to meastasase.
Integrin expression in tumours such as mnoma (Kramer
et al., 1991), neuroblastoma (Favrot et al., 1991) and
osteosarcoma (Lauri et al., 1991) has been extensively
studied. Several studies have also focused on lung cancers
(Damianovich et al., 1992Z Mette et al., 1993; Suzuki et al.,
1993), but have not clarly shown distinct patterns ofintegrin
expresson among various histological types of lung
cancer.
Most lung cancer cell lines as well as normal bronchial
epithlial cells (Strooper et al., 1989) appear to express the A
subunit (Feklman et at., 1991). Although several investigators
(Ruff & Pert, 1984; Bunn et al., 1985; Ball et at., 1986) have
reported the am subunit in a small number of small cell lung
cancer lines, very little expression ofthe P2 subunit was found
on small cell lung cancer cells (Feldman et al., 1991). Our
data from six small cell lung cancer lines were in ageement
with the result of Feldman et al., but all lung cancer cell lines
we eamined, r dss of histological type, showed zero
expresson of the P2 subunit on their surfaces.
Costantini et al. (1990) reported that exprson of the P4
subunit occurs in non-small cell lung cancers, but not in
small cell lung ancers. In our study, P4 was expressd in 7 of
12 non small cell lung cancer lines and in two of seven
small-cel lung cancer lines.
This study showed that the a-subunits most consistently
found on lung cancer cells were 2, a3, aS and a6; a minor
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Figure 5 Ability of tumour cells to adhere to HUVECs. Data of
binding and infiltration into HUVECs represent mean of the
tumour cell number per mm2 ± s.e.m.
population of them expressed ml and a4. There have been
some contradictory reports of a-subunit expression on lung
cancer lines. Mette et al. (1993) found very little expression
of the a5 subunit on non-small cell lung cancers, but Suzuki
et al. (1993) reported that 15 out of 16 non-small cell lung
cancer cell lines expressed m5. Our immunohistochemical
study of integrins showed intensive expression of a5 in app-
roximately half of 34 resected lung cancers (manuscript in
preparation). Damjanovich et al. (1992) reported that normal
bronchial and alveolar epithelial cells exhibit strong expres-
sion of the a2 and a6 subunits, weak expression of al and CX3
and very little or no expression of a and a5. In lung cancer
cells there appears to be up-regulation of a3 and a5 expression
and down-regulation of a, expression. A small number of
lung cancer lines seem to acquire am expression on their
surfaces. Very recently, Mette et al. (1993) reported that lung
cancer cells express the a, subunit. This is associated with the
PI, P3, 05, P6 or 1x subunits (Hynes, 1992). The molecules may
also be important for binding to endothelial cells. Lung
cancer is histologically heterogeneous; the various types are
thought to originate from a wide variety of progenitor cells.
It is clear the expression of integrins on lung cancer cells
must be compared with integrin expression on their pro-
genitor cells. This problem must be addressed in future
studies.
This study clearly showed that most lung cancer lines
adhered to ECM proteins in correspondence to their expres-
sion of integrin subunits. This result suggests that integrins
on lung cancer cells function as receptors for ECM proteins.
Inhibition assays also showed that tumour cell binding to
fibronectin was blocked by RGD peptide in most lung cancer
lines. CS-i1 peptide failed to inhibit tumour cell binding to
fibronectin in LC27 and LC146, although they expressed
VLA-4 on their surfaces. These results suggest that lung
Fiwe 6 Effects of energy and divalent cation on tumour cell
binding to HUVECs. Binding assays were performed at 4C or
3TC. in the presence or absence of divalent cations.
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Figre 7 Effect of MAbs to the P subunit on tumour cell
binding to HUVECs. Using the MAb to integrin P subunit
( , 4B4; or , SG/ 19) or an isotype-identical negative
control MAb, inhibition assays were performed as described in
the Materials and methods section. The MAbs 4B4 and SG'19
greatly inhibited lung cancer cell adhesion to HUVECs.
cancer cells adhere to fibronectin through VLA-3 or VLA-5
on their surfaces, but not through VLA-4. Exceptionallv,
LC142, which did not express any integrin receptors for
collagen, adhered strongly to collagen, and Lu134-A-H,
which did not express any integrin receptors, adhered to
fibronectin. Tumour cell binding to fibronectin in LuI34-A-H
was not blocked by RGD or CS-1 peptide. CD44 adheres to
collagen and fibronectin (Ruoslahti, 1988). LC142 and
LuI34-A-H expressed CD44 (data not shown), and CD44 on
LC142 and LuI34-A-H may be a key adhesion molecule to
adhere to collagen or fibronectin. SBC-1 expressed VLA-6.
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but tumour cells of SBC-I failed to adhere to laminin, sug-
gesting that VLA-6 does not function as a laminin receptor.
LC18 expressed the as subunit with negative staining with
anti-PI (AJ2) and anti-2 antibody (439-9B) and failed to
function as a receptor for collagen, laminin or fibronection.
LC18 reacted with polyclonal antibody RM22 (Bio-Lab. Lit.,
Israel) to the cytoplasmic domain of integrin , subunit (data
not shown). at on LC18 may associate with some variant of
P. The variant VLA-6 appeared not to function as a lamini
receptor.
Our results demonstrated that tumour cell binding to
HUVECs including infiltration of tumour cells into HUVECs
was found in most lung cancer cell lines (16/19), whereas
three lines that expressed very few or no integrin subunits
had very little ability to adhere to HUVECs. The binding of
tumour cells to HUVECs was strongly inhibited at 4C and
under divalent cation-free conditions. These results suggest
that integrins on lung cancer cells play a crucial role in
binding by lung cancer cells to endothelial cells. Lauri et al.
(1991) reported that antiserum to aq8I slightly inhibited bind-
ing of lung cancer cell line A549 to HUVECs (approximately
25% inhibition). We also found that the MAbs to integrin ,
subunit greatly blocked lung cancer cell adhesion to
HUVECs. These results indicated that lung cancer cells
adhere to endothelial cells through the P, subfamily of lung
cancer cells.
The ligands on endothelial cell to integrins of tumour cells
have been investigated. VLA-4 integrin adheres to VCAM-1
on endothelial cells (Hemler et al., 1990; Dedhar et al., 1992).
Very few lung cancer cell lines expressed VLA-4. The other
adhesion molecules on the surface of endothelial cells that
function as ligands of integrins are still unknown. The VLA
subfamily adheres to ECM proteins. HUVECs produce these
ECM proteins (Cagliero et al., 1991), which are located at
the cell-cell borders of endothelial cells (Larmpugnani et al.,
1991). In the HUVEC binding assays most tumour cells
adhered to the cell borders. ECM proteims on the surface of
endothelial cells may adhere to integrins of lung cancer cells,
and thus lung cancer cells may bind and infiltrate into
endothelial cells.
The ICAM-l/LFA-1 (Makgoba et al., 1988), VCAM-1/
VLA-4 (Martin-Padura et al., 1991) and ELAM-I/sialyl-Le
pathways (Walz et al., 1990) appear to be very important
during the process of interaction of myeloma cells and
fibrosarcoma cells to endothelial cells. ICAM-1, VCAM-1
and ELAM-1 on HUVECs are inducible by proinflammatory
cytokines such as IL-1p and TNF-a. Wben using HUVECs
treated with IL-lp and TNF-a, the binding of lung cancer
cells to HUVECs was no greater than when using untreated
HUVECs (data not shown); ICAM-1, ELAM-1 and VCAM-
1 on HUVECs seem to play a minor role in the adhesion of
lung cancer cells to HUVECs in most lung cancer lines.
In our observations integrins on lung cancer cells play a
very important role in the adhesion of lung cancer cells to
endothelial cells and ECM proteins. Clusters ofintegrins may
work synergistically to perform the functions. Integrin ex-
pression on lung cancer cells may be a marker of metastasis.
We recommend investigation of the immunohistochemistry of
integrins using lung cancer tissue specimens and of the cor-
relation between integrin expression and prognosis.
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VCAM-1, vascular cell adhesion molecule 1; VLA, very late activa-
tion antigen.
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